From October 28th to 30th, the global pharmaceutical industry's premier event—CPHI Europe—was held at the Frankfurt Exhibition Center in Germany. Chen Hong, Deputy General Manager of Tianjin Pharmaceutical Group, led a team specializing in the export of active pharmaceutical ingredients and finished products to participate in the exhibition, deeply integrating into the global pharmaceutical industry chain and showcasing the core strength and international flair of Chinese pharmaceutical companies to the world.

The team held intensive business negotiations with over a hundred partners from Europe, North America, the Middle East, and other regions, reaching several consensuses on topics such as product customization, regulatory compliance, and joint development. This fully demonstrated Tianjin Pharmaceutical's competitiveness across the entire supply chain, from R&D and production to quality control. In particular, the company highlighted its commitment to sustainable development, focusing on trends such as green processes and intelligent manufacturing that are of interest to the European and American markets. This further solidified trust within the global supply chain, resulting in new orders and long-term cooperation intentions from multiple regional markets worldwide.

Looking ahead, the company will continue to increase its penetration into the high-end API market, while simultaneously accelerating the overseas registration and capacity expansion of its formulation business, striving to drive a leapfrog development in global formulation sales. The cutting-edge technology resources and market demand information linked through the CPHI platform will directly empower the company to optimize its R&D pipeline and build a global commercial network.

This participation in the exhibition marks a significant milestone in Tianjin Pharmaceutical Group's internationalization journey. Tianjin Pharmaceutical Group consistently adheres to its integrated strategy of API and formulation production, deepening its participation in the global pharmaceutical value chain, and is committed to becoming an innovative pharmaceutical company with international influence.

Manuscript: Tianjin Pharmaceutical Raw Material Sales Center